Akebia Therapeutics
Priced, Nasdaq: AKBABiotech developing a breakthrough anemia treatment with a once-daily oral dose.
Industry: Health Care
First Day Return: +57.1%
AKBA
Biotech developing a breakthrough anemia treatment with a once-daily oral dose.
| IPO Date | 03/19/2014 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $100 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | Cambridge, MA, United States |
|---|---|
| Founded | 2007 |
| Employees at IPO | 28 |
| Website www.akebia.com | |
IPO News for Akebia Therapeutics
Akebia Therapeutics (AKBA) Performance
